Bio-Rad Laboratories, Inc. (BIO) EBITDA Margin: 48.39%
Is Bio-Rad Laboratories, Inc.’s EBITDA margin high or low?
Bio-Rad Laboratories, Inc.'s EBITDA margin of 48.39% is 70% above its 5-year average of 28.49%, around the middle of its 5-year range (-160.19%–199.50%).
As of Wednesday, June 17, 2026. 375.96% above its 12-month average of -17.53%.
BIO EBITDA Margin Chart
BIO Average EBITDA Margin Chart
BIO Current vs Average EBITDA Margin Chart
BIO EBITDA Margin Metrics
EBITDA MARGIN
48.39%
EBITDA MARGIN AVG TTM
-17.53%
EBITDA MARGIN AVG 3Y
-54.94%
EBITDA MARGIN AVG 5Y
28.49%
EBITDA MARGIN AVG 10Y
31.28%
EBITDA MARGIN AVG 15Y
20.31%
EBITDA MARGIN AVG 20Y
16.92%
CURRENT VS TTM AVG
+375.96%
CURRENT VS 3Y AVG
+188.07%
CURRENT VS 5Y AVG
+69.85%
CURRENT VS 10Y AVG
+54.71%
CURRENT VS 15Y AVG
+138.25%
CURRENT VS 20Y AVG
+186.00%
BIO Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.84B | 48.39% | -17.53% | -54.94% | 28.49% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.02B | 7.60% | 6.80% | 0.29% | -7.92% |
| Tempus AI, Inc. (TEM)vs › | $8.82B | -17.48% | -52.76% | -51.11% | -63.28% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 10.23% | 12.29% | 18.59% | 20.64% |
| Baxter International Inc. (BAX)vs › | $10.19B | 6.81% | 8.65% | 4.13% | 9.00% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Revvity, Inc. (RVTY)vs › | $11.29B | 23.20% | 26.85% | 28.84% | 31.56% |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 18.98% | 19.70% | 20.24% | 21.46% |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 25.74% | 26.63% | 26.11% | 26.16% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.18B | 22.55% | 23.25% | 21.70% | 21.08% |
Margin Comparison
Gross Margin
51.9%
EBITDA Margin
48.4%
Operating Margin
9.3%
Net Margin
6.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Bio-Rad Laboratories, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Bio-Rad Laboratories, Inc. (BIO)?
- The EBITDA margin for BIO stock is 48.39%.
- Is Bio-Rad Laboratories, Inc.'s EBITDA margin high or low?
- Bio-Rad Laboratories, Inc.'s EBITDA margin of 48.39% is 70% above its 5-year average of 28.49%, around the middle of its 5-year range (-160.19%–199.50%).
- What is the TTM average EBITDA margin for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average EBITDA margin for BIO stock is -17.53%.
- What is the 3Y average EBITDA margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average EBITDA margin for BIO stock is -54.94%.
- What is the 5Y average EBITDA margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average EBITDA margin for BIO stock is 28.49%.
- What is the 10Y average EBITDA margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average EBITDA margin for BIO stock is 31.28%.
- What is the 15Y average EBITDA margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average EBITDA margin for BIO stock is 20.31%.
- What is the 20Y average EBITDA margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average EBITDA margin for BIO stock is 16.92%.
Bio-Rad Laboratories, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 48.39% |
| 2024-12-31 | -83.46% |
| 2023-12-31 | -24.51% |
| 2022-12-31 | -160.19% |
| 2021-12-31 | 191.21% |
| 2020-12-31 | 199.50% |
| 2019-12-31 | 106.37% |
| 2018-12-31 | 29.46% |
| 2017-12-31 | 12.48% |
| 2016-12-31 | 9.98% |
| 2015-12-31 | 14.82% |
| 2014-12-31 | 13.96% |
| 2013-12-31 | 14.31% |
| 2012-12-31 | 19.55% |
| 2011-12-31 | 19.77% |
| 2010-12-31 | 20.39% |
| 2009-12-31 | 18.75% |
| 2008-12-31 | 15.42% |
| 2007-12-31 | 15.04% |
| 2006-12-31 | 18.01% |
| 2005-12-31 | 14.93% |
| 2004-12-31 | 15.94% |
| 2003-12-31 | 18.88% |
| 2002-12-31 | 20.18% |
| 2001-12-31 | 18.76% |
| 2000-12-31 | 15.16% |
| 1999-12-31 | 13.85% |
| 1998-12-31 | 11.79% |
| 1997-12-31 | 10.80% |
| 1996-12-31 | 13.59% |
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz